Abstract The paradigm of one drug against multiple targets, known as unimolecular polypharmacology, offers the potential to improve efficacy while overcoming some adverse events associated with the treatment
The more responsible approach is to address the systems that actually shape brain aging: metabolic health, cardiovascular risk, sleep, movement, body composition, inflammation, sensory health, hormones, nutrition, and long-term function
A phase 2 study (MARIPOSA randomized trial) demonstrated that, in patients with OSA, administration of aroxybutynin (an antimuscarinic agent) combined with atomoxetine (a norepinephrine reuptake inhibitor) led to modest but significant reductions in AHI (AHI reduction of 5.9 events/hour greater than placebo) over a 4-week period, though the use of atomoxetine was also associated with a reduction of total sleep time by approximately 21 min
[DOI] [PMC free article] [PubMed] [Google Scholar] 82.Nauck M, et al
Overall and liver-related deaths (related to HCC or liver failure), age-standardized mortality rates (ASMR, per 100 000), age at death and years of life lost (YLL) were assessed according to etiology (viral [VIR], alcohol [ALC], MS, autoimmune, genetic, other)
